In the trial SUSTAIN 6 (short for trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects ...

A recent study in Nature Medicine shows semaglutide reduces kidney risks in non-diabetic obese patients with cardiovascular ...

Partly because of this, there has been a recent call to abandon microalbuminuria in favor of the term 'albuminuria-associated disease'. 20,21 This concept has merit when considering the role of ...

(Journal of the American Heart Association) Living kidney donors did not have higher risks of hypertension and albuminuria in ...

Although albuminuria and reduced glomerular filtration rate are believed to be markers of cardiovascular risk in individuals with type 2 diabetes, limited data on the association of these ...

Roughly 2.85 million patients with a qualifying hospital visit were identified with either clinical CKD or at risk for CKD.

The at-home test, known as a semi-quantitative test, uses a urine sample to measure the presence of albumin protein relative ...

Baseline patient characteristics were well-balanced, including kidney function and albuminuria status. The primary endpoint ...

In addition to a 24% reduction in major kidney disease events, the semaglutide group had 18% less MACE at 3 years versus ...

Considering taking supplements to treat albuminuria? Below is a list of common natural remedies used to treat or reduce the symptoms of albuminuria. Follow the links to read common uses ...

In this cohort study of living kidney donors and nondonors with the same follow-up schedule, the risks of hypertension and albuminuria were not significantly different. After the initial drop in ...

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown in the SELECT Trial to be effective in ...